| Official Full Name |
Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2 GMP (rHuTNF-alpha/TNFSF2) |
| Squence |
 |
| Amino Acid Sequence |
MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL |
| Synonyms |
Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor , DIF, Necrosin, Cytotoxin |
| Accession Number |
P01375 |
| GeneID |
7124 |
| Summary |
Tumor necrosis factor alpha (TNF-alpha), also called cachectin, is the best-know member of the TNF-family, which can cause cell death. This protein is produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes endothelial cells, smooth muscle cells and some transformed cells. TNF-alpha occurs as a secreted, soluble form and as a membrane-anchored form, both of which are biologically active. The naturally-occurring form of TNF-alpha is glycosylated, but non-glycosylated recombinant TNF-alpha has comparable biological activity. The biologically active native form of TNF-alpha is reportedly a trimer. Human and murine TNF-alpha show approximately 79 % homology at the amino acid level and cross-reactivity between the two species. Two types of receptors for TNF-alpha have been described and virtually all cell types studied show the presence of one or both of these receptor types. |
| Source |
Escherichia coli. |
| Molecular Weight |
Approximately 17.5 kDa, a single non-glycosylated polypeptide chain containing 158 amino acids. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.05 ng/ml, corresponding to a specific activity of > 2.0 × 107 IU/mg in the presence of actinomycin D. |
| Appearance |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in 10 mM PB, 10 mM NaCl, pH 7.0. |
| Endotoxin |
Less than 0.01 EU/ug of rHuTNF-α/TNFSF2 GMP as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| References |
1. Davenport C, Kenny H, Ashley DT, et al. 2012. Eur J Clin Invest, 42: 1173-9.2. Cavalcanti YV, Brelaz MC, Neves JK, et al. 2012. Pulm Med, 2012: 745483.3. Sheng WS, Hu S, Ni HT, et al. 2005. J Leukoc Biol, 78: 1233-41.4. Berthold-Losleben MandHimmerich H. 2008. Curr Neuropharmacol, 6: 193-202. |
| SDS-PAGE |
 |
| Safety Data Sheet (SDS) Download |
Click to download |
| Technical Data Sheet (TDS) Download |
Click to download |
